Journals / Neurological sciences and neurophysiology (Online) / 2020 / Cilt: 37 - Sayı: 4

Agomelatine is Superior to Melatonin in Pain Suppression: An Experimental Study

Pages
203–207
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The addition of a serotonergic agent increased the antinociceptive effect of melatonin in regard to agomelatine, but high doses of agomelatine were still more effective, suggesting a dose‑dependent effect of agomelatine on 5‑HT2c receptors

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Agomelatine is a synthetic analog of melatonin with selective agonist action on melatonin MT1 and MT2 receptors and antagonistic effect on serotonin 5HT2c receptors.
📊
Key Findings & Data:Methods: Male Wistar albino rats were grouped into seven treatment groups and a control group (8 animals each).
💡
Conclusion & Impact:The addition of a serotonergic agent increased the antinociceptive effect of melatonin in regard to agomelatine, but high doses of agomelatine were still more effective, suggesting a dose‑dependent effect of agomelatine on 5‑HT2c receptors
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Agomelatine is a synthetic analog of melatonin with selective agonist action on melatonin MT1 and MT2 receptors and antagonistic effect on serotonin 5HT2c receptors. Similar to melatonin, it also has antinociceptive properties. There are only a few studies comparing the antinociceptive effects of agomelatine to melatonin. Methods: Male Wistar albino rats were grouped into seven treatment groups and a control group (8 animals each). Treatment groups received intraperitoneal injections of agomelatine 25 mg/kg, 35 mg/kg and 50 mg/kg; agomelatine 35 mg/kg + luzindole 10 mg/kg; melatonin 60 mg/kg and 90 mg/ kg and melatonin 60 mg/kg + sertraline 10 mg/kg. Animals were placed on a hot plate and time to pain avoidance behavior was measured. Results: Agomelatine 25 mg/kg, 35 mg/kg and 50 mg/kg were significantly superior to placebo (all p < 0.0001); agomelatine 35 mg/kg and 50 mg/kg were significantly superior to melatonin 60 mg/kg (p < 0.05 and p < 0.01, respectively) and melatonin 90 mg/kg (p < 0.001 and p < 0.001, respectively) in prolonging reaction times. Agomelatine 50 mg/kg was superior to melatonin 60 mg/kg + sertraline 10 mg/ kg (p < 0,05); on the contrary; agomelatine 25 mg/kg was significantly inferior to this combination in prolonging reaction times (p = 0,041). Melatonin 90 mg/ kg but not 60 mg/kg was significantly superior to placebo in prolonging reaction times (p < 0.0001). Both agomelatine 50 mg/kg and 35 mg/kg were superior to agomelatine 25 mg/kg (p < 0.0001 and p = 0.002, respectively), but the difference between agomelatine 50 mg/kg and 35 mg/kg was not significant. Conclusions: We demonstrated that agomelatine is superior to melatonin on pain behavior in a dose‑dependent manner using an experimental pain model. The addition of a serotonergic agent increased the antinociceptive effect of melatonin in regard to agomelatine, but high doses of agomelatine were still more effective, suggesting a dose‑dependent effect of agomelatine on 5‑HT2c receptors

🔖

Cite This Article

YÜCEL, A. O., BORA, D. D., İŞBİR, M. F., DORA, B. (2020). Agomelatine is Superior to Melatonin in Pain Suppression: An Experimental Study. Neurological sciences and neurophysiology (Online), Cilt: 37 - Sayı: 4, 203–207. https://ajindex.com/articles/290378

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Xu S, Wei W, Shen Y, Hao J, Ding C. Studies on the antiinflamatory, immnoregulatory, and analgesic actions of melatonin. Drug Dev Res 1996;39:167‑73
  2. Calandre EP, Slim M, Garcia‑Leiva JM, Rodriguez‑Lopez CM, Torres P, Rico‑Villademoros F. Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: An uncontrolled, 12‑week, pilot study. Pharmacopsychiatry 2014;47:67-72
  3. Peres MF, Zukerman E, da Cunha Tanuri F, Moreira FR, Cipolla‑Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004;63:757
  4. Leone M, D’Amico D, Moschiano F, Fraschini F, Bussone G. Melatonin versus placebo in the prophylaxis of cluster headache: A double-blind pilot study with parallel groups. Cephalalgia 1996;16:494-6
  5. Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP. Melatonin to prevent migraine or tension-type headache in children. Neurol Sci 2008;29:285-7
  6. Citera G, Arias MA, Maldonado‑Cocco JA, Lázaro MA, Rosemffet MG, Brusco LI, et al. The effect of melatonin in patients with fibromyalgia: A pilot study. Clin Rheumatol 2000;19:9-13
  7. Ambriz‑Tututi M, Granados‑Soto V. Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. Pain 2007;132:273‑80
  8. Wang T, Li SR, Dai X, Peng YL, Chen Q, Wang R. Effects of melatonin on orphanin FQ/nociceptin-induced hyperalgesia in mice. Brain Res 2006;1085:43‑8
  9. Tu Y, Sun RQ, Willis WD. Effects of intrathecal injections of melatonin analogs on capsaicin-induced secondary mechanical allodynia and hyperalgesia in rats. Pain 2004;109:340‑50
  10. Weaver DR, Rivkees SA, Reppert SM. Localization and characterization of melatonin receptors in rodent brain by in vitro autoradiography. J Neurosci 1989;9:2581-90
  11. Williams LM, Hannah LT, Hastings MH, Maywood ES. Melatonin receptors in the brain and pituitary. J Pineal Res 1995;19:173-7
  12. Zahn PK, Lansmann T, Berger E, Speckmann EJ, Musshoff U. Gene expression and functional characterization of melatonin receptors in the spinal cord of the rat: İmplications for pain modulation. J Pineal Res 2003;35:24‑31
  13. Le Grand SM, Patumraj S, Phansuwan‑Pujito P, Srikiatkhachorn A. Melatonin inhibits cortical spreading depression‑evoked trigeminal nociception. Neuroreport 2006;17:1709-13
  14. Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: Role of 5‑HT2C receptor blockade. Psychopha